Last reviewed · How we verify
NCT05312112
Real World Outcomes Using Novel Agents for AML in the UK
trial testing Venetoclax in Acute Myeloid Leukemia in 1,000 participants. Status unknown.
1 October 2023
Quick facts
| Lead sponsor | Guy's and St Thomas' NHS Foundation Trust |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 May 2022 |
| Primary completion | 1 October 2023 |
| Estimated completion | 1 October 2023 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Venetoclax (venetoclax) — full drug profile →
- Gilteritinib (GILTERITINIB) — full drug profile →
Conditions studied
- Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
Sponsor
Guy's and St Thomas' NHS Foundation Trust
Who can join
16 and older, any sex, with Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project will collect data on patients with acute myeloid leukemia in the United Kingdom who were treated with two new targeted therapies during the coronavirus pandemic
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies.
Vandewalle N, De Beule N, De Becker A, De Bruyne E, et al · · 2024 · cited 7× · PMID 39367387 · DOI 10.1186/s40164-024-00566-8
Verify or expand the search:
- PubMed search for NCT05312112
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Venetoclax
Trials testing the same drug.
- NCT07425808 — FLT3-ITD Targeted Therapy in Fit AML Patients · Phase 2, PHASE3 · not yet recruiting
- NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
- NCT07175415 — HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological · Phase 1, PHASE2 · not yet recruiting
- NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
- NCT07511062 — Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML · Phase 1 · not yet recruiting
Other recruiting trials for Acute Myeloid Leukemia
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
- NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
- NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
- NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting
Other Guy's and St Thomas' NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07534917 — Comparing the Effects of Newer Pacemakers and Their Effects on the Heart and Valve Function in the Short-term. · not yet recruiting
- NCT07454135 — Mechanisms of Atrial Pathoelectrophysiology in HCM · not yet recruiting
- NCT07419945 — Older Kidney Patient Optimisation Pretransplant · NA · not yet recruiting
- NCT07309835 — Improving Genetic Medicine for Ethnic Minority Groups · not yet recruiting
- NCT07203872 — Inflammation-resolution Therapy in MINST of Periodontal Intrabony Defect: a Pilot Randomised Controlled Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05312112 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guy's and St Thomas' NHS Foundation Trust
- Last refreshed: 2 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05312112.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing